Literature DB >> 33395747

TNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy.

Matthew M Cousins1, Emily Morris1, Christopher Maurino1, Theresa P Devasia1, David Karnak1, Dipankar Ray1, Neehar D Parikh2, Dawn Owen1, Randall K Ten Haken1, Matthew J Schipper1, Theodore S Lawrence1, Kyle C Cuneo3.   

Abstract

INTRODUCTION: Radiation therapy for the management of intrahepatic malignancies can adversely affect liver function. Liver damage has been associated with increased levels of inflammatory cytokines, including tumor necrosis factor alpha (TNFα). We hypothesized that an inflammatory state, characterized by increased soluble TNFα receptor (sTNFR1), mediates sensitivity of the liver to radiation. MATERIALS/
METHODS: Plasma samples collected during 3 trials of liver radiation for liver malignancies were assayed for sTNFR1 level via enzyme-linked immunosorbent assay (ELISA). Univariate and multivariate logistic regression and longitudinal models were used to characterize associations between liver toxicity (defined as a ≥2-point increase in Child-Pugh [CP] score within 6 months of radiation treatment) and sTNFR1 levels, ALBI score, biocorrected mean liver dose (MLD), age, and baseline laboratory values.
RESULTS: Samples from 78 patients given liver stereotactic body radiation therapy [SBRT] (92%) or hypofractionated radiation were examined. There was a significant association between liver toxicity and sTNFR1 levels, and higher values were associated with increased toxicity over a range of mean liver doses. When ALBI score and biocorrected dose were included in the model with sTNFR1, baseline ALBI score and change in ALBIALBI) were significantly associated with toxicity, but sTNFR1 was not. Baseline aminotransferase levels also predicted toxicity but not independently of ALBI score.
CONCLUSIONS: Elevated plasma sTNFR1 levels are associated with liver injury after liver radiation, suggesting that elevated inflammatory cytokine activity is a predictor of radiation-induced liver dysfunction. Future studies should determine whether administration of agents that decrease inflammation prior to treatment is warranted.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular cancer; Inflammation; Radiation therapy; Soluble tumor necrosis factor receptor 1; TNFR1; TNFα

Year:  2020        PMID: 33395747     DOI: 10.1016/j.tranon.2020.100950

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  4 in total

1.  Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.

Authors:  Matthew M Cousins; Theresa P Devasia; Christopher M Maurino; Justin Mikell; Matthew J Schipper; Ravi K Kaza; Theodore S Lawrence; Kyle C Cuneo; Yuni K Dewaraja
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

2.  The Potential for Midtreatment Albumin-Bilirubin (ALBI) Score to Individualize Liver Stereotactic Body Radiation Therapy.

Authors:  William C Jackson; Holly E Hartman; Laila A Gharzai; Christopher Maurino; David M Karnak; Mishal Mendiratta-Lala; Neehar D Parikh; Charles S Mayo; Randall K Ten Haken; Matthew J Schipper; Kyle C Cuneo; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-04-18       Impact factor: 8.013

3.  Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma.

Authors:  Chih-Weim Hsiang; Wen-Yen Huang; Jen-Fu Yang; Po-Chien Shen; Yang-Hong Dai; Ying-Fu Wang; Chun-Shu Lin; Wei-Chou Chang; Cheng-Hsiang Lo
Journal:  J Hepatocell Carcinoma       Date:  2021-10-29

Review 4.  Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.

Authors:  Franziska Hauth; Hannah J Roberts; Theodore S Hong; Dan G Duda
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.